IceCure Medical Secures New Chinese Patent for Cryogenic Technology Connector

IceCure Medical Ltd. (NASDAQ:ICCM) announced on Monday, November 9, 2026, that the China National Intellectual Property Administration (CNIPA) has granted a new patent covering a connector used in the company’s cryogenic technology platform.

The patent expands IceCure’s intellectual property portfolio, which now comprises 42 patents across the United States, Europe, the United Kingdom, China and Japan.

The patented component forms part of the company’s cryoablation technology, which uses freezing to destroy benign and cancerous tumours as a minimally invasive alternative to surgical removal in certain patients.

Patent Follows Regulatory Approval in China

The patent grant follows IceCure’s receipt of regulatory approval from China’s National Medical Products Administration in September 2026 to market its ProSense cryoablation system and associated cryoprobes.

The company said its intellectual property portfolio covers technologies used in existing products and innovations intended for future development.

IceCure continues to seek patent protection across international markets as part of its technology development and commercialisation activities.

ProSense System Targets Multiple Cancer Types

IceCure’s ProSense system uses liquid nitrogen to freeze and destroy targeted tissue, with applications focused on breast, kidney, bone and lung tumours.

The system is marketed in the United States, Europe and Asia for indications that have received the relevant regulatory clearances or approvals.

In the United States, ProSense has received FDA clearance for the local treatment of breast cancer in patients aged 70 and older with biologically low-risk tumours measuring no more than 1.5 centimetres who are receiving adjuvant endocrine therapy, including patients who are not eligible for surgery.

The latest Chinese patent adds protection for a component of IceCure’s cryogenic platform following the company’s recent regulatory authorisation to market ProSense in China.

IceCure Medical stock price